Literature DB >> 15686266

Neonatal cholestasis.

Sridevi Venigalla1, Glenn R Gourley.   

Abstract

Any infant who is jaundiced beyond two to three weeks of life should be evaluated for neonatal cholestasis. Neonatal cholestasis is defined as accumulation of bile substances in blood due to impaired excretion. These infants should always have fractionated serum bilirubin levels checked to differentiate the conjugated hyperbilirubinemia of cholestasis from unconjugated hyperbilirubinemia that is usually benign and spontaneously resolves. Conjugated hyperbilirubinemia, pale stools and dark urine are the cardinal features of neonatal cholestasis. The differential diagnosis of cholestasis is extensive and a systematic approach is helpful to quickly establish the diagnosis. Biliary atresia is a common cause of neonatal cholestasis and affected infants need surgery before 60 days of life for better prognosis. Premature infants have multifactorial cholestasis and need a modified approach to the evaluation of cholestasis. Management of cholestasis is mostly supportive, consisting of medical management of complications of chronic cholestasis like pruritus and nutritional support for malabsorption and vitamin deficiency.

Entities:  

Mesh:

Year:  2004        PMID: 15686266     DOI: 10.1053/j.semperi.2004.09.008

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  10 in total

1.  Liver disease after intensive care of premature baboons: histopathologic observations.

Authors:  Jay Kerecman; Anupamjit Mehrotra; Zachary Goodman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-08       Impact factor: 2.839

2.  Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic Acid use in neonates.

Authors:  Maxime Thibault; Jessica McMahon; Guillaume Faubert; Julie Charbonneau; Josianne Malo; Ema Ferreira; Ibrahim Mohamed
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

3.  Fecal sphingolipids predict parenteral nutrition-associated cholestasis in the neonatal intensive care unit.

Authors:  Thomas J Moutinho; Deborah A Powers; Gabriel F Hanson; Shira Levy; Rajiv Baveja; Isabel Hefner; Masouma Mohamed; Alaa Abdelghani; Robin L Baker; Jason A Papin; Sean R Moore; Suchitra K Hourigan
Journal:  JPEN J Parenter Enteral Nutr       Date:  2022-03-13       Impact factor: 3.896

Review 4.  Management of severe hyperbilirubinemia in the cholestatic neonate: a review and an approach.

Authors:  Jon F Watchko; M Jeffrey Maisels
Journal:  J Perinatol       Date:  2022-02-10       Impact factor: 3.225

5.  The Value of Hepatic Scintigraphy in the Diagnosis of Biliary Atresia.

Authors:  Wing Ki Chan; Patrick Ho Yu Chung; Kenneth Kak Yuen Wong
Journal:  Front Pediatr       Date:  2022-05-31       Impact factor: 3.569

6.  Biopsy-driven diagnosis in infants with cholestatic jaundice in Iran.

Authors:  Elham Talachian; Ali Bidari; Mitra Mehrazma; Nahid Nick-khah
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

7.  Definitive exclusion of biliary atresia in infants with cholestatic jaundice: the role of percutaneous cholecysto-cholangiography.

Authors:  Benedict C Nwomeh; Donna A Caniano; Mark Hogan
Journal:  Pediatr Surg Int       Date:  2007-09       Impact factor: 1.827

Review 8.  Italian guidelines for the management and treatment of neonatal cholestasis.

Authors:  Carlo Dani; Simone Pratesi; Francesco Raimondi; Costantino Romagnoli
Journal:  Ital J Pediatr       Date:  2015-10-01       Impact factor: 2.638

9.  Evaluation of cholestasis in Iranian infants less than three months of age.

Authors:  Seyed Mohsen Dehghani; Neda Efazati; Iraj Shahramian; Mahmood Haghighat; Mohammad Hadi Imanieh
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

Review 10.  Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects.

Authors:  Lena E Gottesman; Michael T Del Vecchio; Stephen C Aronoff
Journal:  BMC Pediatr       Date:  2015-11-20       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.